Theranostics — the integration of diagnostic imaging with targeted therapy using a single agent or platform — has become one of the more clinically meaningful developments in modern oncology. The core appeal is straightforward: by using the same molecule to both locate and treat disease, clinicians can directly confirm target expression before committing to therapy, and monitor response during it. This review covers the major theranostic imaging techniques currently in clinical and investigational use, including PET/SPECT-paired radionuclide therapies, nanoparticle-based multimodal platforms, photoacoustic and photothermal approaches, and targeted alpha therapy. The two FDA-approved agents — ¹⁷⁷Lu-DOTATATE for neuroendocrine tumours and ¹⁷⁷Lu-PSMA-617 for metastatic castration-resistant prostate cancer — are reviewed in detail, drawing on data from the VISION and TheraP trials.We also examine Actinium-225 as the leading alpha-emitting candidate, the growing interest in biomimetic nanotheranostic platforms, and the early integration of AI into dosimetry workflows. On the practical side, the field still faces real constraints: radiopharmaceutical supply is limited, patient access is uneven, dosimetry remains technically demanding, and long-term safety data are still accumulating. Taken together, the evidence suggests theranostics is moving from niche nuclear medicine into mainstream precision oncology — but getting there will require coordinated work across multiple disciplines.